1. Time to disease flare was significantly shorter in the placebo group versus baricitinib. 2. There was no difference in serious adverse events between the baricitinib and placebo groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Juvenile idiopathic arthritis (JIA) is defined by the onset of polyarticular joint pain before age 16 and can severely
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Cosentyx® shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal Phase III trials
Novartis Cosentyx® shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal Phase III trials streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Results from two parallel trials show Cosentyx (secukinumab) demonstrated superior efficacy vs placebo with statistically significant improvement in hidradenitis suppurativa (HS) signs and symptoms1Safety